Offering an early switch to VOCABRIA + REKAMBYS, after achieving virologic suppression, empowers patients with their preferred treatment choice while maintaining virologic suppression[1]
Introducing VOLITION
A phase IIIb study where people naive to treatment started with daily oral DTG/3TC. Participants who were virologically suppressed*, between Week 4 and Week 16, were then given the choice to either continue with daily oral DTG/3TC or switch to 2-monthly VOCABRIA + REKAMBYS.[1]
What participants chose
When offered the choice after achieving virologic suppression, over 8 out of 10 eligible participants in the VOLITION study chose to switch to VOCABRIA + REKAMBYS[1]
Proportion of eligible participants (n=151) who chose to switch to every-2-month VOCABRIA + REKAMBYS vs continuing with daily oral therapy:*[1]
For 8 out of 10 participants, not having to worry about missing a daily dose was the main reason for switching[1]
Avoid worrying about missed daily doses (80%; n=103/129)
Over 7 out of 10 participants felt the option to switch fit better with their lifestyle,[1]
“The option to switch fits my life better” (76%; n=96/127)
*A total of 171 participants enrolled and initiated DTG/3TC, of whom 151 (88%) participants met the eligibility criteria and were offered the option to switch to every-2-month VOCABRIA + REKAMBYS at the Day of Choice.[1]
High rate of virologic suppression and low rate of confirmed virologic failure (CVF) with resistance through Month 11 after early switch to VOCABRIA + REKAMBYS[1]
Co-primary endpoint: Per modified* snapshot algorithm, 88% (n=113/129) of participants maintained virologic suppression (HIV-1 RNA <50 copies/mL) at Month 11.†[1]
Observed‡ virologic suppression (HIV-1 RNA <50 copies/mL) at Month 11[1]
Have you discussed VOCABRIA + REKAMBYS with your recently suppressed eligible patients?
Learn about the impact of shared decision making
Have you discussed VOCABRIA + REKAMBYS with your recently suppressed eligible patients?
Learn about the impact of shared decision making
Could your patients naive to treatment benefit from an early switch to VOCABRIA + REKAMBYS immediately following virologic suppression?
Learn more about why patients may prefer VOCABRIA + REKAMBYS to daily oral therapy
Co-primary endpoint: Median time to virologic suppression from baseline with DTG/3TC was 4.1 weeks (95% CI: 4.1, 4.3).[1]
*In the modified snapshot algorithm, RealTime HIV-1 RNA results were prioritised over the cobas 6800 assay when available and within the snapshot window.[1]
†Of the remaining 16 participants: 10 (7.8%) had no virologic data in the analysis window due to discontinuation from the study (for reasons other than adverse events or death) and six (4.7%) had HIV-1 RNA ≥50 copies/mL.[1]
‡Includes only participants with available virologic data in-window.[1]
§CVF definition: two consecutive measurements of plasma HIV-1 RNA ≥200 copies/mL after prior suppression to HIV-1 RNA <50 copies/mL.[1]
‖Includes only participants who received VOCABRIA + REKAMBYS and responded to the questionnaire. Where percentages do not sum to 100%, this is due to rounding.[1]
Prescribing Information and Adverse Event Reporting for DOVATO (dolutegravir/lamivudine) is available here.
CI=confidence interval; CVF=confirmed virologic failure; DTG/3TC=dolutegravir/lamivudine; HIV=human immunodeficiency virus; HIV-1=human immunodeficiency virus type 1; RNA=ribonucleic acid.
REKAMBYS (rilpivirine long-acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned or licensed by the ViiV Healthcare group. ©2026 ViiV Healthcare group of companies or its licensor. All rights reserved.
PM-GB-CBR-WCNT-250009 v3 | June 2026
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
